{
    "Trade/Device Name(s)": [
        "HemosIL FII & FV DNA Control"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K093737",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083171"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NZB"
    ],
    "Summary Letter Date": "March 31, 2010",
    "Summary Letter Received Date": "April 1, 2010",
    "Submission Date": "December 3, 2009",
    "Regulation Number(s)": [
        "21 CFR 866.5910"
    ],
    "Regulation Name(s)": [
        "Quality Control, Genetics, DNA"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "coagulation"
    ],
    "Analyte(s)": [
        "Factor II (20210G>A)",
        "Factor V (1691G>A Leiden)"
    ],
    "Specimen Type(s)": [
        "Whole Blood (simulated matrix)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GeneXpert Dx System"
    ],
    "Method(s)/Technology(ies)": [
        "Extraction",
        "Amplification",
        "Detection"
    ],
    "Methodologies": [
        "Genotyping",
        "DNA mutation analysis"
    ],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL FII & FV DNA Control as a heterozygous quality control for Factor II and Factor V genotyping on the GeneXpert Dx System.",
    "Indications for Use Summary": "For in vitro diagnostic use as a heterozygous quality control to monitor analytical performance of the Xpert HemosIL FII & FV genotyping assay on the GeneXpert Dx System used in detecting Factor II (20210G>A) and Factor V (1691G>A Leiden) mutations.",
    "fda_folder": "Microbiology"
}